High expression of adhesion molecules/activation markers with little interleukin-2, interferon γ, and tumor necrosis factor β gene activation in fresh tumor-infiltrating lymphocytes from lung adenocarcinoma Eugène RousselMarie-Claude GingrasJack A. Roth Original Article Pages: 1 - 9
Therapy of bovine ocular squamous-cell carcinoma with local doses of interleukin-2: 67% complete regressions after 20 months of follow-up Willem Den Otter F. W.Graham HillVictor P. M. G. Rutten Original Article Pages: 10 - 14
Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells Cecilia BallaréMarcela BarrioJose Mordoh Original Article Pages: 15 - 22
Interferons up-regulate with different potency HLA class I antigen expression in M14 human melanoma cell line. Possible interaction with glucocorticoid hormones Lorella LanzaLorenza PeiranoMarco Scudeletti Original Article Pages: 23 - 28
Pharmacokinetics of anti-ganglioside GD2 mAb 14G2a in a phase I trial in pediatric cancer patients Martina M. Uttenreuther-FischerChuin-Sheng HuangAlice L. Yu Original Article Pages: 29 - 36
Treating tumor-bearing mice with vitamin D3 diminishes tumor-induced myelopoiesis and associated immunosuppression, and reduces tumor metastasis and recurrence M. Rita I. YoungJoe IhmM. Margaret Prechel Original Article Pages: 37 - 45
Antibody-independent phagocytosis of tumor cells by human monocyte-derived macrophages cultured in recombinant macrophage colony-stimulating factor David H. MunnNai-Kong V. Cheung Original Article Pages: 46 - 52
In vitro and in vivo antitumour activity of a chimeric anti-CD19 antibody Geoffrey A. PieterszLi WenjunJoseph A. Trapani Original Article Pages: 53 - 60
Lymphocytes infiltrating colorectal cancer have low proliferative capacity but can secrete normal levels of interferon γ Wendy J. BatemanImelda DonnellanAlan G. Morris Original Article Pages: 61 - 67
Graft-versus-host disease following interleukin-2/lymphokine-activated killer (LAK) cell immunotherapy in a patient with acute myelogenous leukaemia in second complete remission: autologous LAK cells following allogeneic bone marrow transplantation are donor-derived Brian J. BoughtonAndrew W. SimpsonCynthia Beatty Short Communication Pages: 68 - 70